Poor
Not Aligned
Patient Risk:
Medium
Summary
The evaluated claims focus on brand-name identity (linking “Neosar” to cyclophosphamide) and drug class labeling. The provided label section (11 DESCRIPTION) describes cyclophosphamide but does not mention “Neosar” or explicit class wording like “alkylating,” so key identity and mechanism/class claims are unsupported.
Category Scores
Accurate Statements
Cyclophosphamide is soluble in water, saline, or ethanol.
11 DESCRIPTION states cyclophosphamide is soluble in water, saline, or ethanol.
The active ingredient substance described is cyclophosphamide.
11 DESCRIPTION describes cyclophosphamide as the drug substance and provides chemical/physical details.
Unsupported Statements
Neosar is a brand name of cyclophosphamide.
11 DESCRIPTION describes cyclophosphamide but does not mention the brand name “Neosar,” so the brand-to-active ingredient linkage is not supported.
Cyclophosphamide is an alkylating chemotherapy drug.
11 DESCRIPTION describes cyclophosphamide as a synthetic antineoplastic drug chemically related to nitrogen mustards, but does not explicitly state it is an “alkylating chemotherapy drug.”
Neosar is one of the marketed names used for cyclophosphamide formulations.
11 DESCRIPTION does not mention “Neosar” or any marketed brand names.
Neosar refers to a brand product.
11 DESCRIPTION contains no information indicating that “Neosar” is a brand product.
The active ingredient in Neosar is cyclophosphamide.
While cyclophosphamide is described, the provided label section does not link cyclophosphamide to the brand “Neosar.”
Different companies may market cyclophosphamide under other brand names.
11 DESCRIPTION does not discuss other companies or other brand names.
Contradictions
Important Omissions
No reviewable label-aligned statements were provided regarding dosing/administration, contraindications, boxed warnings, warnings/precautions, interactions, monitoring, storage/handling, or specific populations.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Medium
The unsupported brand-to-active ingredient and class/mechanism wording could misidentify the product and/or intended drug characterization, which is a labeling accuracy concern. No dosing or safety-critical assertions were provided in the evaluated claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Brand-name identity linkage (“Neosar” ↔ cyclophosphamide) and explicit class/mechanism labeling are not supported by the provided label section (11 DESCRIPTION).
Suggested Improvement
Restrict claims to what 11 DESCRIPTION supports (i.e., cyclophosphamide description and formulation details) and avoid asserting any brand-name linkage or explicit “alkylating chemotherapy” class wording unless supported by additional label sections that mention “Neosar.”